Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer – Appraisal Consultation Document 2

DRAFT guidance does not recommend abiraterone & prednisone/prednisolone plus androgen deprivation for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. Cost-effectiveness estimates were higher than normally considered a cost-effective use of NHS resources.

National Institute for Health and Care Excellence